Gynecologic and Obstetric Investigation · 2010 · 17 citations · 0 references
MedicineOncologyPathologyCancer ImmunologyGynecologic OncologyTumor ImmunologyCervical CancerCervical LesionsCervical PathologyEndometrial CancerSquamous Cell CarcinomaCervical Carcinoma In SituInvasive Carcinoma AssessmentInvasive Cervical CarcinomaSquamous Cell Carcinoma Pathology
The serum concentrations of the tumor-associated antigen SCC were determined in 62 patients with invasive carcinoma of the uterine cervix. Antigen values above 2.0 ng/ml were considered as slightly positive, and those above 4.0 ng/ml as highly positive. Pretherapeutic levels were elevated (greater than 2.0 ng/ml) in 68% of the patients with cervical carcinoma. In 49 patients with carcinoma in situ, 18% of the SCC values were above the normal range. The greatest incidence of positive SCC titers (84%) was observed in women with recurrent cervical carcinoma. Only 6.7% of women in remission had elevated titers. Five of 24 cases (21%) with invasive endometrial carcinoma had SCC values exceeding 2.0 ng/ml. Slightly positive levels of tumor antigen were seen in 1.8% (1/56) of the control subjects. Serial SCC determinations revealed a correlation with the clinical course of disease in 84%. The determination of SCC is useful for the surveillance of patients with cervical squamous cell carcinoma.